Gio Talk - Novel treatment strategy in NSCLC

eLearning on BoehringerOne

Visit BoehringerOne.com

Giotalk Intensive	Duration
Session 1 Advancements in the treatment of NSCLC with driver mutations	26:00
Session 2 Treatment in Lung cancer – Post Pandemic	14:00
Session 3 Upfront treatment strategy in early stage EGFRm+ NSCLC	16:00
Session 4 Novel treatment strategy in advanced EGFRm+ NSCLC	18:00
Session 5 Emerging treatment strategy in advanced EGFRm+ NSCLC	19:00
Session 6 How best utilize the real-world evidence in advanced EGFRm+ NSCLC	10:00
Session 7 How to choose better therapeutic IO biomarkers for patients with NSCLC	16:00
Session 8 How to make the best use of IO as first-line treatment of advanced NSCLC	21:00
Session 9 How to overcome IO resistance in NSCLC – Novel approaches and outlook	22:00
Session 10 What’s next for IO in early-stage NSCLC?	14:00
Session 11 The evolving landscape of biomarker testing for non-small cell lung cancer for targeted therapy	13:00
Session 12 What’s new for the treatment targeting antibody-drug conjugate in NSCLC	19:00
Session 13 What’s new for the treatments targeting HER2 and Exon20 mutations?	12:00
Session 14 What’s new for the treatments targeting KRAS mutations, MET exon 14 and MET amplification?	22:00

Giotalk_Module 3: Novel treatment strategy in NSCLC